-
Posted by
Two Blokes Jun 5 -
Filed in
Stock
-
2 views
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that Sandra Silberman, M.D., Ph.D., Chief Medical Officer of CNS Pharmaceuticals, will present at the Lenox Hill Hospital, Department of Neurosurgery's Brain Tumor Biotech Summit being held on June 5, 2025 in New York, NY.
